Targeted screening and treatment of chronic kidney disease: Lessons learned from the Kidney Early Evaluation Program

Disease Management and Health Outcomes

Volumn 14, Issue 6, 2006, Pages 341-352

  Vassalotti, Joseph A ^a,b   Gracz Weinstein, Leslie ^a   Gannon, Monica R ^a   Brown, Wendy Weinstock ^c,d  

^a NATIONAL KIDNEY FOUNDATION   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CHOLESTEROL; CREATININE; TRIACYLGLYCEROL;

ALBUMINURIA; ANEMIA; AWARENESS; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; COMORBIDITY; DEMOGRAPHY; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; DIALYSIS; DISEASE CLASSIFICATION; DISEASE COURSE; EARLY DIAGNOSIS; GLOMERULUS FILTRATION RATE; HEALTH CARE COST; HEALTH CARE ORGANIZATION; HEALTH INSURANCE; HEALTH PROGRAM; HUMAN; HYPERTENSION; KIDNEY TRANSPLANTATION; MORTALITY; OBESITY; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PATIENT EDUCATION; QUESTIONNAIRE; REVIEW; RISK FACTOR; SCREENING;

EID: 33846301986     PISSN: 11738790     EISSN: None     Source Type: Journal    
DOI: 10.2165/00115677-200614060-00004     Document Type: Review

References (36)

1. Coresh J, Byrd-Holt D, Astor B, et al. Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000. J Am Soc Nephrol 2005; 16: 180-8
2. US Renal Data System. USRDS 2005 annual data report. Bethesda (MD): National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2005
3. Collins AJ, Couser WG, Dirks JH, et al. World Kidney Day: an idea whose time has come. Kidney Int 2006; 69: 781-2
4. Hamer RA, El Nahas AM. The burden of chronic kidney disease. BMJ 2006; 332: 563-4
5. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 2002; 39: S1-266
6. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-701
7. Stevens LA, Coresh J, Greene T, et al. Assessing kidney function: measured and estimated glomerular filtration rate. N Engl J Med 2006; 354: 2473-83
8. Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005; 67: 2089-100
9. Myers G, Miller W, Coresh J, et al. Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program. Clin Chem 2006; 52: 5-18
10. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32: S112-19
11. Foley RN, Murray AM, Li S, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol 2005; 16: 489-95
12. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-305
13. Anavekar NS, McMurray JJ, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351: 1285-95
14. Nissenson AR, Collins AJ, Dickmeyer J, et al. Evaluation of disease-state management of dialysis patients. Am J Kidney Dis 2001; 37: 938-44
15. Chen RA, Scott S, Mattern WD, et al. The case for disease management in chronic kidney disease. Dis Manag 2006; 9: 86-92
16. Trivedi HS, Pang MM, Campbell A, et al. Slowing the progression of chronic renal failure: economic benefits and patients' perspectives. Am J Kidney Dis 2002; 39: 721-9
17. Rodby RA, Firth LM, Lewis EJ. An economic analysis of captopril in the treatment of diabetic nephropathy. The Collaborative Study Group. Diabetes Care 1996; 19: 1051-61
18. Gerth WC, Remuzzi G, Viberti G, et al. Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL study for the European Union. Kidney Int 2002; 62 Suppl. 82: 68-72
19. Stevens LA, Fares G, Fleming J, et al. Low rates of testing and diagnostic codes usage in a commercial clinical laboratory: evidence for lack of physician awareness of chronic kidney disease. J Am Soc Nephrol 2005; 16: 2439-48
20. Buckalew Jr VM, Berg RL, Wang SR, et al. Prevalence of hypertension in 1,795 subjects with chronic renal disease: the modification of diet in renal disease study baseline cohort. Modification of Diet in Renal Disease Study Group. Am J Kidney Dis 1996; 28: 811-21
21. Collins AJ, Li S, Ma JZ, et al. Cardiovascular disease in end-stage renal disease patients. Am J Kidney Dis 2001; 38: S26-9
22. Arora P, Obrador GT, Ruthazer R, et al. Prevalence, predictors, and consequences of late nephrology referral at a tertiary care center. J Am Soc Nephrol 1999; 10: 1281-6
23. Kinchen KS, Sadler J, Fink N, et al. The timing of specialist evaluation in chronic kidney disease and mortality. Ann Intern Med 2002; 137: 479-86
24. Brown WW, Peters RM, Ohmit SE, et al. Early detection of kidney disease in community settings: the Kidney Early Evaluation Program, Am J Kid Dis 2003; 42: 22-35
25. Brown WW, Collins A, Chen S, et al. Identification of persons at high risk for kidney disease via targeted screening: the NKF Kidney Early Evaluation Program, Kidney Int, 2003; 63: S50-5
26. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154-69
27. National Kidney Foundation. Kidney Early Evaluation Program. Am J Kidney Dis 2005; 45: S1-135
28. National Kidney Foundation. Kidney early evaluation program: 2006 annual data report. Am J Kidney Dis 2007. In press
29. National Kidney Foundation. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 2004; 43: S1-290
30. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-72
31. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86
32. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53
33. National Kidney Foundation. K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease. Am J Kidney Dis 2003; 41: S1-76
34. Kalantar-Zadeh K, Fouque D, Kopple JD. Outcome research, nutrition, and reverse epidemiology in maintenance dialysis patients. J Ren Nutr 2004; 14: 64-71
35. National Kidney Foundation. K/DOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006; 47: S1-145
36. El-Achkar TM, Ohmit SE, McCullough PA, et al. Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: The Kidney Early Evaluation Program. Kidney Int 2005; 67: 1483-8